Recent progress in clinical research of mRNA technologies

As the first mRNA-based COVID-19 vaccine received Emergency Use Authorization (EUA) in 2020, its great safety profile and high protection efficacy has been well demonstrated. As a result of its unique advantage in the mechanism of action, mRNA can effectively trigger strong humoral and cellular immune response. Of note, many other prophylactic or therapeutic mRNA vaccines developed for preventing different infectious diseases or treatment of cancer are under clinical trial investigations. mRNA-based protein supplementation and gene therapy also begin to emerge. There will be bigger stage for the development of mRNA technology-based products, posing a revolutionary effect in the field of biopharmaceuticals.